MERREM Drug Patent Profile

When do Merrem patents expire, and what generic alternatives are available?

Merrem is a drug marketed by Pfizer and is included in one NDA.

The generic ingredient in MERREM is meropenem. There are thirty-two drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the meropenem profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Merrem

A generic version of MERREM was approved as meropenem by ACS DOBFAR on October 26^th, 2011.

Summary for MERREM

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	84
Clinical Trials:	15
Patent Applications:	4,356
Drug Prices:	Drug price information for MERREM
What excipients (inactive ingredients) are in MERREM?	MERREM excipients list
DailyMed Link:	MERREM at DailyMed

See drug prices for MERREM

Recent Clinical Trials for MERREM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Wake Forest University Health Sciences	Phase 4
Johns Hopkins University	Phase 2
Hoffmann-La Roche	Phase 1

See all MERREM clinical trials

US Patents and Regulatory Information for MERREM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	MERREM	meropenem	INJECTABLE;INJECTION	050706-001	Jun 21, 1996	AP	RX	Yes	Yes
Pfizer	MERREM	meropenem	INJECTABLE;INJECTION	050706-003	Jun 21, 1996	AP	RX	Yes	Yes

Expired US Patents for MERREM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	MERREM	meropenem	INJECTABLE;INJECTION	050706-001	Jun 21, 1996
Pfizer	MERREM	meropenem	INJECTABLE;INJECTION	050706-003	Jun 21, 1996

International Patents for MERREM

See the table below for patents covering MERREM around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	S59205379	NOVEL BETA-LACTAM COMPOUND AND PRODUCTION THEREOF
Japan	H0551594
Germany	3486382
Japan	S6355514

Supplementary Protection Certificates for MERREM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2603514	SPC/GB19/021	United Kingdom		PRODUCT NAME: VABORBACTAM, AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE.; REGISTERED: UK EU/1/18/1334 (NI) 20181120; UK PLGB 16239/0061 20181120
2603514	2019014	Norway		PRODUCT NAME: A COMBINATION OF VABORBACTAM, AND/OR A SALT AND/OR HYDRATE THEREOF, AND MEROPENEM, AND/OR A SALT AND/OR HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE; REG. NO/DATE: EU/1/18/1334/001 20181122
2603514	CA 2019 00015	Denmark		PRODUCT NAME: EN KOMBINATION AF VABORBACTAM, OG/ELLER ET SALT OG/ELLER HYDRAT DERAF, OG MEROPENEM, OG/ELLER ET SALT OG/ELLER HYDRAT DERAF, SAERLIGT MEROPENEM TRIHYDRAT; REG. NO/DATE: EU/1/18/1334 20181122
3412676	PA2020519,C3412676	Lithuania		PRODUCT NAME: VABORBAKTAMO IR (ARBA) JO DRUSKOS, IR (ARBA) HIDRATO BEI MEROPENEMO IR (ARBA) JO DRUSKOS, IR (ARBA) HIDRATO, YPAC MEROPENEMO TRIHIDRATO, DERINYS; REGISTRATION NO/DATE: EU/1/18/1334 20181120

MERREM Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Merrem (Meropenem)

Overview of Merrem (Meropenem)

Merrem, also known as meropenem, is a carbapenem antibiotic that belongs to the broader class of beta-lactam antibiotics. It is widely used to treat a variety of severe bacterial infections, including intra-abdominal infections, meningitis, nosocomial pneumonia, and others[5].

Global Market Size and Growth

The global meropenem API market is projected to expand significantly over the coming years. As of 2024, the market size is estimated to be in the millions of USD, with a compound annual growth rate (CAGR) of 4.00% from 2024 to 2031[1].

Regional Market Share

• North America: This region dominates the global meropenem API market, accounting for around 40% of the global revenue. The high prevalence of hospital-acquired infections (HAIs) and the increasing susceptibility of the elderly population to these infections drive the demand for meropenem in this region[1].
• Asia Pacific: This region is experiencing rapid growth, driven by the escalation of antibiotic resistance, expanding healthcare awareness, and the availability of generic versions. The Asia Pacific region held around 23% of the global revenue in 2024 and is expected to grow at a CAGR of 6.0% from 2024 to 2031[1].
• Latin America: The market in Latin America accounts for around 5% of the global revenue and is expected to grow at a CAGR of 3.4% from 2024 to 2031. The increasing awareness of antimicrobial resistance and the use of broad-spectrum antibiotics like meropenem are key drivers[1].
• Middle East and Africa: This region holds a smaller share, around 2% of the global revenue, but is expected to grow at a CAGR of 3.7% from 2024 to 2031[1].

Drivers of Market Growth

Increasing Prevalence of Antibiotic-Resistant Bacteria

The rising prevalence of antibiotic-resistant bacteria is a significant driver of the meropenem market. Meropenem remains effective against many strains of bacteria that are resistant to other antibiotics, making it a crucial treatment option[4].

Hospital Formularies and Generic Availability

Meropenem is often included in hospital formularies, which are lists of approved medications for use within the hospital setting. The availability of generic versions of meropenem, particularly in the Asia Pacific region, has made the drug more accessible and affordable, contributing to its market growth[1][4].

Economic and Pharmacodynamic Benefits

Pharmacodynamically influenced dosage strategies for meropenem have shown to reduce drug costs without compromising efficacy. For instance, a study demonstrated that lower dosage regimens of meropenem could reduce daily costs by $38.64 compared to standard regimens, making it a more economically viable option[2].

Market Challenges

Supply Chain Disruptions

The COVID-19 pandemic highlighted weaknesses in the global supply chain of meropenem API, which is heavily dependent on a few significant producers from China and India. Lockdowns and production halts during the pandemic led to temporary shortages and instability in the market[1].

Economic Uncertainty

Long-term healthcare resource shortages and persistent economic uncertainty due to the pandemic may impede industry expansion. Despite the long-term demand fueled by concerns about antibiotic resistance, these factors could slow down the market's growth rate[1].

Financial Trajectory

Revenue Projections

The global carbapenem market, which includes meropenem, was valued at USD 3.62 billion in 2022 and is expected to grow at a CAGR of 4.78% from 2023 to 2030, reaching USD 5.24 billion by 2030. Meropenem accounted for the largest share of this market, with a significant portion of the revenue[4].

Pricing and Cost Considerations

The cost of meropenem can vary significantly depending on the region and the specific formulation. For example, in the U.S., the cost for Merrem 500 mg intravenous powder for injection can range from $161.65 to $358.82 for a supply of 10 powder for injection. Generic versions are available at lower prices, starting from $31.94 for 10 powder for injection[5].

Patient Assistance Programs

To make meropenem more accessible, patient assistance programs (PAPs) and copay cards are available. These programs, such as the HealthWell Foundation Copay Program, provide financial assistance to eligible individuals to cover coinsurance, copayments, and healthcare premiums[5].

Key Players

The meropenem market is dominated by several key players, including:

• Menarini Group
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd
• Lupin
• Kopran Limited
• Aurobindo Pharma
• Daewoong Pharmaceuticals Co., Ltd.
• Shenzhen Haibin Pharmaceutical Co. Ltd.
• Merck & Co., Inc.[4]

Application Outlook

Meropenem is used to treat a variety of bacterial infections, including:

• Urinary Tract Infections
• Bloodstream Infections
• Intra-abdominal Infections
• Pneumonia
• Skin and Soft Tissue Infections[4]

Distribution Channels

The distribution of meropenem is primarily through:

• Hospital Pharmacies
• Retail Pharmacies[4]

Conclusion

The market for meropenem is driven by the increasing prevalence of antibiotic-resistant bacteria, the inclusion in hospital formularies, and the availability of generic versions. Despite challenges such as supply chain disruptions and economic uncertainty, the market is expected to grow significantly over the next few years. The financial trajectory indicates a strong revenue growth, with key players continuing to innovate and expand their market share.

Key Takeaways

• The global meropenem API market is expected to grow at a CAGR of 4.00% from 2024 to 2031.
• North America dominates the market, followed by the Asia Pacific region.
• The increasing prevalence of antibiotic-resistant bacteria is a major driver of the market.
• Pharmacodynamically influenced dosage strategies can reduce costs without compromising efficacy.
• Patient assistance programs and generic availability make meropenem more accessible.

FAQs

1. What is the primary use of meropenem? Meropenem is primarily used to treat severe bacterial infections such as intra-abdominal infections, meningitis, nosocomial pneumonia, and others.

2. Which region dominates the global meropenem API market? North America dominates the global meropenem API market, accounting for around 40% of the global revenue.

3. How does the COVID-19 pandemic impact the meropenem market? The COVID-19 pandemic caused temporary shortages and instability in the meropenem API market due to supply chain disruptions and production halts in key producing countries like China and India.

4. What are the economic benefits of pharmacodynamically influenced dosage strategies for meropenem? These strategies can reduce daily costs by $38.64 compared to standard regimens without compromising efficacy.

5. Are there patient assistance programs available for meropenem? Yes, patient assistance programs such as the HealthWell Foundation Copay Program provide financial assistance to eligible individuals to cover costs associated with meropenem.

Sources

1. Cognitive Market Research: Meropenem API Market Report 2024 (Global Edition)
2. PubMed: Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts
3. SAGE Journals: Comparing Outcomes of Meropenem Administration Strategies
4. Grand View Research: Carbapenem Market Size & Share Report, 2030
5. Drugs.com: Merrem Prices, Coupons, Copay Cards & Patient Assistance